Immunoassay-aptasensor for the determination of tumor-derived exosomes based on the combination of magnetic nanoparticles and hybridization chain reaction

Zhang, Hua; Zhou, Yajuan; Luo, Dan; Liu, Jingjian; Yang, Enlai; Yang, Ge; Feng, Guangjun; Chen, Qinhua; Wu, Lun

doi:10.1039/d0ra10159a

Cited by 13 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al, achieved lower LOD but narrow liner range compared to the proposed sensing assay. They have also employed ultracentrifugation prior to detection of EVs that lengthens the detection operation [31]. Recently published research establish that PD-L1@EVs can be used for the diagnosis of LC [28] and breast cancer [32].…”

Section: Discussionmentioning

confidence: 99%

Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles

Khan

et al. 2022

Biosensors

View full text Add to dashboard Cite

Cancer specific extracellular vesicles (EVs) are of significant clinical relevance, for instance programmed death ligand-1 (PD-L1) expressing EVs (PD-L1@EVs) have been shown to be ideal biomarker for non-invasive diagnosis of cancer and can predate the response of cancer patients to anti-PD-1/PD-L-1 immunotherapy. The development of sensitive and straightforward methods for detecting PD-L1@EVs can be a vital tool for non-invasive diagnosis of cancer. Most of the contemporary methods for EVs detection have limitations such as involvement of long and EV’s loss prone isolation methods prior to detection or they have employed expensive antibodies and instruments to accomplish detection. Therefore, we designed an ultracentrifugation-free and antibody-free sensing assay for PD-L1@EV by integrating Titanium oxide (TiO2) coated magnetic beads (Fe3O4@TiO2) rapid capturing of EVs from undiluted serum with aptamers specificity and chemiluminescence (CL) sensitivity. To accomplish this we used Fe3O4@TiO2 beads to rapidly capture EVs from the undiluted patient serum and added biotin labelled PD-L1 aptamer to specifically recognize PD-L1@EVs. Later, added streptavidin-modified Alkaline phosphates (ALP) taking advantage of biotin-streptavidin strong binding. Addition of CDP-star, a chemiluminescent substrate of ALP, initiates the chemiluminiscense that was recorded using spectrophotometer. The sensing assay showed high sensitivity with limit of detection (LOD) as low as 2.584×105 EVs/mL and a wider linear correlation of CL intensity (a.u.) with the concentration of PD-L1@EVs from 105 to 108 EVs/mL. To examine the clinical utility of sensing assay we used undiluted serum samples from lung cancer patients and healthy individuals and successfully discern between healthy individuals and lung cancer patients. We are optimistic that the sensing assay can ameliorate our ability to be able to diagnose lung cancer non-invasively and can be helpful to predate the patient’s response to anti-PD-1/PD-L1 immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles

Khan

et al. 2022

Biosensors

View full text Add to dashboard Cite

show abstract

“…Furthermore, as such sandwich assays often require a dual-site recognition of the target, aptamers and antibodies complement each other in this manner [150]. Sandwich aptamer-antibody biosensors have been developed for different targets, such as proteins [152,154,155,[158][159][160][161][162], antibiotics [163,164], bacteria [165,166] and fungi [167,168] in various biosensing platforms. These have been recently summarized in an excellent review by Jarczewska and Malinowska [150].…”

Section: Hybrid Systemsmentioning

confidence: 99%

“…Antibody-aptamer hybrid biosensors employing HCR amplification were also reported [151,172,173]. For example, Zhang et al have applied this approach for fluorescence-assisted detection of tumorrelated exosomes [162], where the exosomes were sandwiched between CD63 antibody-functionalized magnetic nanoparticles and oligonucleotides, comprising of a PDL-1 (Programmed death-ligand 1) targeting aptamer and an initiator of HCR. In such hybrid systems, the antibody and the aptamer capture probes can be also employed simultaneously as demonstrated by Ma et al [174] for the detection of mucin 1, a cancer protein biomarker.…”

Section: Hybrid Systemsmentioning

confidence: 99%

Aptasensors versus immunosensors—Which will prevail?

Arshavsky‐Graham

Heuer

Xin

et al. 2022

Engineering in Life Sciences

View full text Add to dashboard Cite

Since the invention of the first biosensors 70 years ago, they have turned into valuable and versatile tools for various applications, ranging from disease diagnosis to environmental monitoring. Traditionally, antibodies have been employed as the capture probes in most biosensors, owing to their innate ability to bind their target with high affinity and specificity, and are still considered as the gold standard. Yet, the resulting immunosensors often suffer from considerable limitations, which are mainly ascribed to the antibody size, conjugation chemistry, stability, and costs. Over the past decade, aptamers have emerged as promising alternative capture probes presenting some advantages over existing constraints of immunosensors, as well as new biosensing concepts. Herein, we review the employment of antibodies and aptamers as capture probes in biosensing platforms, addressing the main aspects of biosensor design and mechanism. We also aim to compare both capture probe classes from theoretical and experimental perspectives. Yet, we highlight that such comparisons are not straightforward, and these two families of capture probes should not be necessarily perceived as competing but rather as complementary. We, thus, elaborate on their combined use in hybrid biosensing schemes benefiting from the advantages of each biorecognition element.

show abstract

“…[77][78][79][80][81] Owing to the flexible structure, the corresponding DNA can be ultrasensitively and homogeneously detected by previously reported DNA-based signal amplification methods, such as terminal deoxynucleotidyl transferase (TdT)-mediated polymerization and hybridization chain reaction (HCR). [82][83][84][85][86][87][88][89] For example, Gao et al reported a dual signal amplification method for indirect detection of exosomes based on the catalytic hairpin DNA cascade reaction (HDCR) and the self-assembly of DNA dendrimer on the surface of gold nanoparticles (Au NPs). 90 In this work, streptavidin (SA)-modified MBs were labeled with biotin-modified CD63 aptamer and then bound with probe S through the hybridization.…”

Section: Nanomaterials-based Optical Biosensors For Exosome Detection Fluorescence Biosensorsmentioning

confidence: 99%

Progress in Nanomaterials-Based Optical and Electrochemical Methods for the Assays of Exosomes

Ma¹,

Hao²,

Liu³

2021

IJN

View full text Add to dashboard Cite

Immunoassay-aptasensor for the determination of tumor-derived exosomes based on the combination of magnetic nanoparticles and hybridization chain reaction

Abstract: The detection of tumor-related exosomes is of great significance.

Cited by 13 publications

References 36 publications

Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles

Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles

Aptasensors versus immunosensors—Which will prevail?

Progress in Nanomaterials-Based Optical and Electrochemical Methods for the Assays of Exosomes

Contact Info

Product

Resources

About